Drug Abuse PreventionNCT07064343
Stand By Me: Anti-Drug Elite Adventure-Based Training Program
A study testing Aspirin in people with Drug Abuse Prevention, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
Trial summary
This project is expected to establish a network of resilient young people with good anti-drug knowledge to mobilize them to assist in current or future anti-drug work, expanding the antidrug capacity of our community. Read more about this study
- Who is it for?
- Ages 18 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Drug Abuse Prevention
- What is being tested?
- Aspirin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteHong Kong
- Study dates
- 9 Sep 2024to 8 Sep 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- post-secondary or tertiary education students,
- aged 18 - 35,
- able to speak in Cantonese and write in Chinese.
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Hong Kong1 site, 1 recruiting
- Recruiting
The Hong Kong Polytechnic University
Hong Kong
Katherine Lam, 27666420, kw-katherine.lam@polyu.edu.hk
About this study
This project is expected to establish a network of resilient young people with good anti-drug knowledge to mobilize them to assist in current or future anti-drug work, expanding the antidrug capacity of our community. After the project, it is also anticipated that people in this network will continue to assist in the anti-drug work.
Read the detailed description
In phase 1, the investigators will deliver adventure-based training programs (2-day 1-night camp). Participants will attend in the educational workshop and undergo five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
- Conditions
- Drug Abuse Prevention
- Being tested
- Aspirin
- Keywords
- Health Promotion, Drug Abusers, The AWARD model, Adventure-based Training Program
- Medical subject headings
- Drug Misuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AspirinOther
Also called adventure-based training program
Participants are required to complete the training program includes an educational workshops and five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Participants will attend an two day one night adventure-based training program which includes an educational workshop and five adventure-based activities. Receives: Other: Aspirin |
What is being measured
The primary outcome is the main question the study is designed to answer.
BDF Question Set No. 2
To assess knowledge about the harm of drug abuse. Scoring Instruction: Q1 + Q2 + Q3 + Q4 + Q5 + (6-Q6) + Q7 + Q8 + Q9 + Q10. Minimum score: 10 Maximum score: 50.
Measured: Baseline and 2 days (pre and post intervention)
BDF Question Set No. 24
Knowledge about Cannabis-related Harms. Minimum score: 12 Maximum score: 60. total score calculate: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7+ Q8 + Q9 + Q10 + (6-Q11) + (6-Q12).
Measured: baseline and 2 days (pre and post intervention)
BDF Question Set No. 18
To assess permissive attitude towards drug abuse (Secondary school student version). Minimum score: 21 Maximum score: 105. Total scores calculate: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7 + Q8 + Q9 + Q10 + Q11 + Q12 + Q13 + Q14 + Q15 + Q16 + Q17 + Q18 + Q19 + Q20 + Q21.
Measured: Baseline and 2 days (pre and post intervention)
BDF Question Set No. 25
To assess permissive attitude towards smoking cannabis. Minimum score: 13 Maximum score: 65. Calculate process: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7+ Q8 + Q9 + Q10 + Q11 + Q12 + Q13.
Measured: baseline and 2 days (pre and post intervention)
BDF Question Set No. 26
To assess permissive attitude towards drugs trafficking. Minimum score: 14 Maximum score: 70. Total scores calculate: Q1 + Q2 + (6-Q3) + Q4 + (6-Q5) + Q6 + (6-Q7) + (6-Q8) + Q9 + Q10 + (6-Q11) + Q12 + Q13.
Measured: Baseline and 2 days (pre and post intervention)
The Chinese version of the 14-item resilience scale
The 14-item resilience scale (RS-14) was used to assess the degree of resilience and was a short version of the original resilience scale (RS). The RS-14 was a 14-item and single-factor structure instrument, comprising a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Examples of the items were, "I feel that I can handle many things at a time" and "I keep interested in things". The Chinese translation of the RS-14 was developed with a backtranslation procedure to ensure accuracy. Suitable internal consistency was suggested by a figure of .917 for the coefficient alpha (regarding the RS-14 of the original scale). Further, the original RS-14 was retested after three weeks, and the test-retest reliability of RS-14 was .736 (.595, .837).
Measured: Baseline and 2 days (pre and post intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start9 Sep 2024
- Primary completion8 Sep 2025 (estimated)
- Study completion8 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Drug Abuse PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Hong Kong Polytechnic University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Katherine Lam, The Hong Kong Polytechnic University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07064343
- Sponsor's protocol ID
- BDF_ Anti-drug Elite
- Status last verified
- Nov 2024
- First submitted
- 27 Mar 2025
- Last updated
- 14 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stand By Me: Anti-Drug Elite Adventure-Based Training Program
- ClinicalTrials.gov ID
- NCT07064343
- Acronym / sponsor ID
- BDF_ Anti-drug Elite
- Conditions
- Drug Abuse Prevention
- Keywords
- Health Promotion, Drug Abusers, The AWARD model, Adventure-based Training Program
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- The Hong Kong Polytechnic UniversityUniversity, hospital or other
- Study start
- 9 Sep 2024 (actual)
- Primary completion
- 8 Sep 2025 (estimated)
- Study completion
- 8 Sep 2025 (estimated)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project is expected to establish a network of resilient young people with good anti-drug knowledge to mobilize them to assist in current or future anti-drug work, expanding the antidrug capacity of our community. After the project, it is also anticipated that people in this network will continue to assist in the anti-drug work.
Detailed description
In phase 1, the investigators will deliver adventure-based training programs (2-day 1-night camp). Participants will attend in the educational workshop and undergo five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: AspirinParticipants will attend an two day one night adventure-based training program which includes an educational workshop and five adventure-based activities. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- post-secondary or tertiary education students,
- aged 18 - 35,
- able to speak in Cantonese and write in Chinese.
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AspirinAlso: adventure-based training programParticipants are required to complete the training program includes an educational workshops and five adventure-based activities. The key educational workshop's topics include: 1) introduction to the drugs, health and legal consequences of drugs especially cocaine, cannabis and ice, 2) anti-drug services, and 3) the AWARD model. | Other | Intervention group |
Primary outcome
BDF Question Set No. 2
Time frame: Baseline and 2 days (pre and post intervention)
To assess knowledge about the harm of drug abuse. Scoring Instruction: Q1 + Q2 + Q3 + Q4 + Q5 + (6-Q6) + Q7 + Q8 + Q9 + Q10. Minimum score: 10 Maximum score: 50.
BDF Question Set No. 24
Time frame: baseline and 2 days (pre and post intervention)
Knowledge about Cannabis-related Harms. Minimum score: 12 Maximum score: 60. total score calculate: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7+ Q8 + Q9 + Q10 + (6-Q11) + (6-Q12).
BDF Question Set No. 18
Time frame: Baseline and 2 days (pre and post intervention)
To assess permissive attitude towards drug abuse (Secondary school student version). Minimum score: 21 Maximum score: 105. Total scores calculate: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7 + Q8 + Q9 + Q10 + Q11 + Q12 + Q13 + Q14 + Q15 + Q16 + Q17 + Q18 + Q19 + Q20 + Q21.
BDF Question Set No. 25
Time frame: baseline and 2 days (pre and post intervention)
To assess permissive attitude towards smoking cannabis. Minimum score: 13 Maximum score: 65. Calculate process: Q1 + Q2 + Q3 + Q4 + Q5 + Q6 + Q7+ Q8 + Q9 + Q10 + Q11 + Q12 + Q13.
BDF Question Set No. 26
Time frame: Baseline and 2 days (pre and post intervention)
To assess permissive attitude towards drugs trafficking. Minimum score: 14 Maximum score: 70. Total scores calculate: Q1 + Q2 + (6-Q3) + Q4 + (6-Q5) + Q6 + (6-Q7) + (6-Q8) + Q9 + Q10 + (6-Q11) + Q12 + Q13.
The Chinese version of the 14-item resilience scale
Time frame: Baseline and 2 days (pre and post intervention)
The 14-item resilience scale (RS-14) was used to assess the degree of resilience and was a short version of the original resilience scale (RS). The RS-14 was a 14-item and single-factor structure instrument, comprising a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Examples of the items were, "I feel that I can handle many things at a time" and "I keep interested in things". The Chinese translation of the RS-14 was developed with a backtranslation procedure to ensure accuracy. Suitable internal consistency was suggested by a figure of .917 for the coefficient alpha (regarding the RS-14 of the original scale). Further, the original RS-14 was retested after three weeks, and the test-retest reliability of RS-14 was .736 (.595, .837).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Drug Abuse Prevention
Active, not recruiting
Implementing PrEP for Women Who Inject Drugs
HIV, Intravenous Substance Abuse
Not yet recruiting
Clinician Practice Companion to Address Youth Substance Use
Substance Use, Substance-Related Disorders
Active, not recruiting
Evaluation of Effectiveness of the LifeSkills Training - Lombardia - Primary Shool Program ( Val3P-LST )
Well Being, Drug Addiction
Recruiting
Wakaya: Rising Up for Choctaw Youth Health
Obesity, Adolescent, Healthy Nutrition
Not yet recruitingObservational study
Evaluation of Clinical Decision Support in Opioid Tapering
Medication Abuse, Harm Reduction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Aspirin in people with Drug Abuse Prevention, run by The Hong Kong Polytechnic University at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ka Wai Katherine Lam (27666420, kw-katherine.lam@polyu.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
BDF Question Set No. 2 (time frame: Baseline and 2 days (pre and post intervention)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2025.